ALLMedicine™ Follicular Lymphoma Center
Research & Reviews 4,725 results
https://doi.org/10.1007/s00259-021-05275-6
European Journal of Nuclear Medicine and Molecular Imaging; Sollini M, Gelardi F et. al.
Feb 27th, 2021 - Complete remission of follicular lymphoma after SARS-CoV-2 infection: from the "flare phenomenon" to the "abscopal effect".|2021|Sollini M,Gelardi F,Carlo-Stella C,Chiti A,|
https://doi.org/10.1182/bloodadvances.2020003129
Blood Advances; Diefenbach CS, Peters BA et. al.
Feb 26th, 2021 - B-cell non-Hodgkin lymphoma cell survival depends on poorly understood immune evasion mechanisms. In melanoma, the composition of the gut microbiota (GMB) is associated with immune system regulation and response to immunotherapy. We investigated t...
https://doi.org/10.1007/s00277-021-04470-7 10.1038/s41408-020-0299-0 10.1200/JCO.19.01073 10.1038/leu.2014.251 10.1182/blood-2003-12-4434 10.1200/JCO.2008.21.3991 10.1016/S1470-2045(15)00169-2 10.1182/blood-2017-11-816405 10.1093/annonc/mdf198 10.1002/ajh.23708 10.1182/blood.v128.22.1102.1102 10.1016/j.jgo.2019.10.003 10.1007/s12185-016-2099-7 10.1200/JCO.18.00400 10.1200/JCO.1997.15.3.1110 10.1016/0021-9681(87)90171-8 10.1200/JCO.2006.09.2403 10.1214/aos/1176350951 10.3324/haematol.2018.187773
Annals of Hematology; Mozas P, Rivero A et. al.
Feb 25th, 2021 - Frailty and concurrent medical conditions are crucial factors in the management of follicular lymphoma (FL). We evaluated the impact of age and comorbidity on survival, causes of death, histological transformation (HT), and second malignancies (SM...
https://doi.org/10.1177/1066896921995942
International Journal of Surgical Pathology; Lin YS, Hamilton AER et. al.
Feb 23rd, 2021 - Collision tumors are rare and there have only been a few previously described cases between an intestinal adenoma and a lymphoma. We report the first case of a 74-year-old woman who on investigation for iron deficiency had a tubulovillous adenoma ...
https://doi.org/10.1038/s41408-021-00430-6 10.1172/JCI110005 10.2217/fon.15.57 10.1002/cpt.1396 10.1038/icb.2014.93 10.1038/srep17943 10.1002/ijc.23626 10.1016/j.ebiom.2019.102625 10.1158/1078-0432.CCR-18-0455 10.1182/blood-2011-10-387969 10.1097/CJI.0000000000000199 10.1126/scitranslmed.aaa4802 10.1073/pnas.1220145110 10.1038/nprot.2014.169 10.1200/JCO.2020.38.15_suppl.8009 10.1038/bcj.2015.1 10.1093/annonc/mdg201 10.1097/01.ftd.0000184162.60197.c1 10.1200/JCO.1998.16.12.3916 10.1182/blood-2008-08-175208 10.1111/j.1349-7006.2008.01005.x
Blood Cancer Journal; van der Horst HJ, de Jonge AV et. al.
Feb 19th, 2021 - Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from...
Guidelines 31 results
https://doi.org/10.1016/j.annonc.2020.11.008
Annals of Oncology : Official Journal of the European Soc... Dreyling M, Ghielmini M et. al.
Nov 29th, 2020 - Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Dreyling M,Ghielmini M,Rule S,Salles G,Ladetto M,|
https://www.healio.com/hematology-oncology/lymphoma/news/online/{87e5706a-8ecb-4473-95b8-60f27a6e22cb}/off-the-shelf-car-t-regimen-safe-for-advanced-lymphoma
May 31st, 2020 - An allogeneic chimeric antigen T-cell therapy plus an anti-CD52 monoclonal antibody appeared safe for certain patients with large B-cell or follicular lymphoma, according to study data presented during the ASCO20 Virtual Scientific Program.
https://www.onclive.com/conference-coverage/asco-2020/off-the-shelf-cart-cell-therapy-allo501-induces-high-responses-in-relapsed-refractory-bcell-lymphomas
May 29th, 2020 - The allogeneic chimeric antigen receptor (CAR)-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, has clinical activity and a manageable safety profile in patients with relapsed/refractory large B-cell or follicular lymphoma. T...
https://www.targetedonc.com/view/novel-car-t-cell-therapy-combination-shows-preliminary-activity-in-r-r-b-cell-lymphoma
May 28th, 2020 - First-in-human findings show that ALLO-501, an allogeneic chimeric antigen receptor (CAR)-T cell therapy plus ALLO-647, a monoclonal antibody, has clinical activity and is tolerable in patients with relapsed/refractory large B-cell or follicular l...
https://ashpublications.org/hematology/article-abstract/2019/1/287/422587/Where-does-transplant-fit-in-the-age-of-targeted?redirectedFrom=fulltext
ASH Clinical News; Chow VA,et al
Dec 5th, 2019 - The role of hematopoietic cell transplantation (HCT) for indolent lymphoma has evolved over the last 5 years with the availability of novel low-toxicity therapies and a better understanding of the prognosis of these entities. However, despite nume...
Drugs 21 results see all →
Clinicaltrials.gov 5,119 results
https://doi.org/10.1007/s00259-021-05275-6
European Journal of Nuclear Medicine and Molecular Imaging; Sollini M, Gelardi F et. al.
Feb 27th, 2021 - Complete remission of follicular lymphoma after SARS-CoV-2 infection: from the "flare phenomenon" to the "abscopal effect".|2021|Sollini M,Gelardi F,Carlo-Stella C,Chiti A,|
https://doi.org/10.1182/bloodadvances.2020003129
Blood Advances; Diefenbach CS, Peters BA et. al.
Feb 26th, 2021 - B-cell non-Hodgkin lymphoma cell survival depends on poorly understood immune evasion mechanisms. In melanoma, the composition of the gut microbiota (GMB) is associated with immune system regulation and response to immunotherapy. We investigated t...
https://doi.org/10.1007/s00277-021-04470-7 10.1038/s41408-020-0299-0 10.1200/JCO.19.01073 10.1038/leu.2014.251 10.1182/blood-2003-12-4434 10.1200/JCO.2008.21.3991 10.1016/S1470-2045(15)00169-2 10.1182/blood-2017-11-816405 10.1093/annonc/mdf198 10.1002/ajh.23708 10.1182/blood.v128.22.1102.1102 10.1016/j.jgo.2019.10.003 10.1007/s12185-016-2099-7 10.1200/JCO.18.00400 10.1200/JCO.1997.15.3.1110 10.1016/0021-9681(87)90171-8 10.1200/JCO.2006.09.2403 10.1214/aos/1176350951 10.3324/haematol.2018.187773
Annals of Hematology; Mozas P, Rivero A et. al.
Feb 25th, 2021 - Frailty and concurrent medical conditions are crucial factors in the management of follicular lymphoma (FL). We evaluated the impact of age and comorbidity on survival, causes of death, histological transformation (HT), and second malignancies (SM...
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/zuma-5-axicabtagene-ciloleucel-elicits-response-in-indolent-non-hodgkin-lymphoma/
Feb 24th, 2021 - In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American Society of Hematology (ASH) Annual Meeting & E...
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/epov-james-essell/
Feb 24th, 2021 - James Essell, MD, Medical Director of the Blood Cancer Center, The Jewish Hospital-Mercy Health Cincinnati Cancer and Cellular Therapy Center, and Chair of Cellular Therapy, observed that axicabtagene ciloleucel compares favorably with other chime...
News 489 results
https://www.medscape.com/viewarticle/945426
Feb 7th, 2021 - The US Food and Drug Administration (FDA) has granted accelerated approval to umbralisib (Ukoniq) for the treatment of adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and...
https://www.medscape.com/viewarticle/942494
Dec 10th, 2020 - For the first time, a chimeric antigen receptor (CAR) therapy has yielded a high response rate among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), including patients with follicular lymphoma (FL) and marginal zone lymphom...
https://www.staging.medscape.com/viewarticle/939347
Oct 18th, 2020 - Tazemetostat (Tazverik) showed potential for improving outcomes for patients with advanced or metastatic epithelioid sarcoma and also yielded clinically meaningful responses in heavily pretreated patients with follicular lymphoma. The findings com...
https://www.medscape.com/viewarticle/939347
Oct 18th, 2020 - Tazemetostat (Tazverik) showed potential for improving outcomes for patients with advanced or metastatic epithelioid sarcoma and also yielded clinically meaningful responses in heavily pretreated patients with follicular lymphoma. The findings com...
